Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (28)

« Back to Publications

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2026), Am J Kidney Dis, 87, 564 - 568

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Scotland G. et al, (2025), Diabet Med, 42

Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes.

Sammons E. et al, (2025), BMJ Open, 15

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 771 - 779

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.

Pessoa-Amorim G. et al, (2024), Trials, 25

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group ., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group . et al, (2022), Eur Heart J, 43, 1416 - 1424

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

ASCEND Study Collaborative Group . et al, (2018), N Engl J Med, 379, 1529 - 1539

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.

ASCEND Study Collaborative Group . et al, (2018), N Engl J Med, 379, 1540 - 1550

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.

Bowman L. et al, (2018), Am Heart J, 198, 135 - 144

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

HPS3/TIMI55–REVEAL Collaborative Group . et al, (2017), N Engl J Med, 377, 1217 - 1227

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

REVEAL Collaborative Group . et al, (2017), Am Heart J, 187, 182 - 190

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.

Reith C. et al, (2017), BMC Nephrol, 18

Why use cdisc for trials not submitted to regulators? Lessons from the experience of an academic clinical trial unit

Wallendszus K. et al, (2017), TRIALS, 18

Load More